CureGBM

CureGBM is a clinical-stage MedTech company bringing Sonodynamic Therapy to European patients with glioblastoma.

Standard care for glioblastoma has not changed in 30 years. In early Phase 1 trials in the United States, SDT doubled survival in patients with recurrent glioblastoma. Zero therapy-related adverse events. Non-invasive. Outpatient. Repeatable quarterly.

CureGBM is launching the second SDT trial for glioblastoma in Europe at Inselspital, University Hospital Bern, Switzerland in late 2026. The trial is free for patients across the UK and Europe.

Support the trial: www.curegbm.co.uk/skipyourcoffee

For every tomorrow. 💜